医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Machine Learning and Medicine: Yawlih’s Rapid Rise in China

2018年01月22日 PM11:00
このエントリーをはてなブックマークに追加


 

BEIJING

Yawlih Healthcare Analytics recently raised USD 2 million in a Pre-A round of investment led by Vision+ Capital. This injection of capital will be used to enhance Yawlih’s leadership in the development of machine learning algorithms and predictive analytics in hospital information systems throughout China.

“China’s healthcare market is booming and so is innovation in AI. Our partnership with Vision+ Capital is not only a material boost to our company, it also shows confidence from our investors that Yawlih is making big gains in learning algorithms and hospital informatics,” says Yawlih CEO and founder Dr. Jeff Hsu.

Yawlih’s flagship product suite – Willow – is used by China’s leading hospitals to aggregate disparate data sources into a single database where algorithms transform raw data into predictive insights that supports individual clinical decisions as well as forecasting changes in population health and large-scale disease occurrence.

Developing this end-to-end SaaS platform was not an easy feat. “Our leadership team brings together engineers with medical experts who understand both the software and the medical world. Since the end users are usually physicians and medical staff, we knew we had to design a product that leveraged medical technology as much as it does artificial intelligence,” says Chris Young, Yawlih’s Head of Operations.

But the Yawlih team sees even greater possibilities on the horizon.

“From day one, our vision and product have been guided by designs which are both scalable and flexible. We see Willow having applications not only in a hospital environment, but also clinical trials, the health insurance market, supply chain optimization, academic research and even augmented reality,” Dr. Hsu says.

“For Yawlih, technology is just the beginning – we want to make an impact not just on technology, but on the people and the processes to make our mission transformative for everyone involved,” continues Dr. Hsu. “We are excited to continue developing with the support of Vision+ Capital not only as a financial partner, but also as a strategic advisor for our next generation of products.”

For more information, visit Yawlih’s website.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180122005087/en/

CONTACT

Yawlih Healthcare Analytics
Jeff Hsu, MD, +86 186-106-01484
or
Christopher
Young, +86 186 0016 0061

同じカテゴリーの記事 

  • Inocras Pioneers Precision Health with Revolutionary Whole Genome Insights
  • エクセルゲン、バクスター・インターナショナルを提訴。口腔体温計の精度に関するデータの公表権を擁護
  • パース・バイオサイエンシズが研究室用自動化プロバイダー・プログラムをローンチし、ハミルトン、オープントロンズ、ラボワークス、SPTラボテックと提携
  • Parse Biosciences与Hamilton、Opentrons Labworks和SPT Labtech合作推出实验室自动化供应商计划
  • Charting New Paths: Mannatech Expanding with Thailand Office, Grand Opening, September 2024